CARsgen Therapeutics

CARsgen Therapeutics is an innovative company dedicated to chimeric antigen receptor (CAR)-T cell immunotherapy. Currently, the company has initiated the world’s first CAR-T clinical trial for hepatocellular carcinoma (HCC) and a globally leading CAR-T clinical trial for glioblastoma (GBM). CARsgen Therapeutics holds more than 50 domestic and international patents, including those related to fourth-generation CAR-T technology. The company has independently established a fully human antibody library and a humanized antibody technology platform for developing tumor-targeting antibodies, and has independently developed highly specific CAR-T candidate products capable of targeting a broad range of solid tumors and hematologic malignancies.